Petros Pharmaceuticals, Inc. (PTPI) Key Metrics
PTPI valuation today
Trailing 12 months · as of October 21, 2026- Market cap
- $127,116
- Enterprise value
- −$1.5M
- P/E (TTM)
- 0.0
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 0.5
- Price / book
- 0.2
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.88
PTPI key metrics, 2018–2025
Fiscal year ended December 31, 2025 · U.S. dollarsPTPI returns How much profit the business earns on the capital it uses.
PTPI financial health Debt, liquidity and how easily interest is covered.
PTPI returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
PTPI debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
PTPI cash returned to shareholders
PTPI key metrics
2018–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Share price at fiscal year-end | $0.01 | $9.85 | $35.25 | $58.25 | $832.50 | $1,100.00 | — | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | — | — | −55.9% | −76.7% | −33.9% | −161.5% | — | — |
| Return on invested capital (ROIC) | — | — | −87.5% | −107.5% | −140.8% | −98.4% | −49.0% | −14.1% |
| Return on assets (ROA) | 24.2% | −64.5% | −24.7% | −40.2% | −13.1% | −32.1% | −51.9% | −48.5% |
| Return on tangible assets | 37.1% | −192.7% | −0.1% | −0.1% | −0.0% | −54.6% | −166.3% | −159.6% |
| Free cash flow margin | — | −51.4% | −131.0% | −213.6% | −151.9% | −160.2% | 15.8% | 43.7% |
| Income quality (OCF / net income) | −3.52 | — | — | — | — | — | — | — |
| Financial health | ||||||||
| Total debt | — | $7.4M | $8.3M | $9.9M | $405,018 | $7.8M | $13.7M | $47.2M |
| Cash & short-term investments | $5.1M | $3.7M | $13.3M | $9.4M | $23.8M | $17.1M | $2.1M | $2.8M |
| Net debt | −$5.1M | $3.7M | −$5.1M | $456,530 | −$23.4M | −$9.3M | $11.6M | $44.4M |
| Debt / equity | — | — | 0.66 | 0.59 | 0.01 | 0.45 | 1.71 | — |
| Debt / assets | — | 0.69 | 0.24 | 0.30 | 0.01 | 0.11 | 0.24 | 0.71 |
| Net debt / EBITDA | — | — | — | — | — | — | — | 118.84 |
| Current ratio | 2.25 | 0.40 | 1.89 | 2.08 | 0.99 | 0.62 | 0.29 | 0.41 |
| Quick ratio | 2.25 | 0.24 | 1.74 | 1.82 | 0.97 | 0.60 | 0.24 | 0.24 |
| Interest coverage | — | -31.5 | -25.4 | -33.4 | -49.0 | -5.7 | -1.4 | — |
| Working capital | $2.9M | −$10.7M | $9.6M | $7.6M | −$437,381 | −$16.0M | −$29.0M | −$22.7M |
| Invested capital | −$2.3M | −$3.8M | $7.4M | $17.2M | $12.1M | $8.1M | $19.6M | $42.7M |
| Tangible asset value | $2.9M | −$10.7M | $8.97B | $25.29B | $25.28B | −$14.7M | −$30.8M | −$48.2M |
| Net current asset value | $2.9M | −$10.8M | −$925,376 | −$1.1M | −$1.3M | −$26.5M | −$38.3M | −$52.8M |
| Capital allocation | ||||||||
| Dividends paid | $974.0M | $1.29B | $556.7M | — | — | — | — | — |
| Share buybacks (net) | $341,560 | $6.2M | $2.0M | $0 | — | — | — | — |
| Capex / revenue | — | 0.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.5% | 13.3% |
| Capex / operating cash flow | — | — | — | — | — | — | 2.8% | 23.4% |
| Capex / depreciation | — | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.23 |
| Stock-based compensation / revenue | — | 3.9% | 7.2% | 19.9% | 16.7% | 38.0% | 34.7% | — |
| R&D / revenue | — | 51.2% | 41.4% | 29.0% | 22.9% | 4.8% | — | — |
| SG&A / revenue | — | 171.1% | 159.8% | 203.8% | 199.6% | 164.0% | 126.6% | 80.4% |
| Efficiency | ||||||||
| Days sales outstanding | — | 94.3 | 135.9 | 157.6 | 192.0 | 171.8 | 86.2 | 91.2 |
| Days of inventory on hand | — | 693.7 | 383.2 | 186.1 | 146.1 | 133.7 | 124.8 | 226.0 |
| Days payables outstanding | — | 608.3 | 393.8 | 507.3 | 1,160.0 | 423.3 | 79.3 | 61.0 |
| Cash conversion cycle (days) | — | 179.7 | 125.4 | -163.6 | -822.0 | -117.8 | 131.7 | 256.2 |
| Receivables turnover | — | 3.87 | 2.69 | 2.32 | 1.90 | 2.12 | 4.23 | 4.00 |
| Payables turnover | 0.00 | 0.60 | 0.93 | 0.72 | 0.31 | 0.86 | 4.60 | 5.98 |
| Inventory turnover | — | 0.53 | 0.95 | 1.96 | 2.50 | 2.73 | 2.93 | 1.61 |
| Asset turnover | 0.00 | 0.23 | 0.18 | 0.12 | 0.11 | 0.15 | 0.25 | 0.21 |
| Average receivables | — | $1.3M | $2.2M | $2.6M | $4.1M | $4.5M | $3.7M | $3.5M |
| Average payables | $1.2M | $2.0M | $1.8M | $3.2M | $5.1M | $4.7M | $2.8M | $1.8M |
| Average inventory | — | $2.3M | $1.7M | $1.2M | $640,090 | $1.5M | $4.3M | $6.5M |
| Intangibles / total assets | 0.0% | 30.1% | −26,493.8% | −77,938.7% | −37,457.4% | 46.0% | 66.5% | 69.6% |
Computed from PTPI's annual financial statements (latest annual report filed April 15, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
PTPI valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 0.0. It returned $974.3 million to shareholders: $974.0 million in dividends and $0.3 million in share buybacks.
See the PTPI income statement, the PTPI chart for price history, or the PTPI stock overview for the latest quote and news.
PTPI key metrics FAQ
What is Petros Pharmaceuticals's P/E ratio?
Petros Pharmaceuticals's trailing P/E ratio is 0.0 based on the last twelve months of earnings (as of October 21, 2026). At the end of fiscal 2025 it was —.
Does Petros Pharmaceuticals buy back its shares?
Yes. Petros Pharmaceuticals spent $0.3 million on net share repurchases in fiscal 2025.
What is Petros Pharmaceuticals's current ratio?
Petros Pharmaceuticals's current ratio was 2.25 at the end of fiscal 2025: current assets were 2.25 times current liabilities.